Heterodimeric interleukin 15(Novartis Pharma)

N/A

Report date: 2024/01/17 20:00:38

Base Information

Drug NameHeterodimeric interleukin 15(Novartis Pharma)
Drug Alias NamehetIL-15sIL 15RaHeterodimeric IL-15NIZ-985
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 receptor subunit alpha agonistsInterleukin-15 stimulants
TargetsInterleukin-15 receptor subunit alphaInterleukin-15
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma

Other Information

ATC CodeN/A
Related LinksN/A